Lumigan in the United States: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in the United States under the regulatory framework of FDA (Food and Drug Administration). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- FDA (Food and Drug Administration)
- Currency
- USD
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in the United States
In the US, most prescription medications require a written or e-prescription from a licensed prescriber. A handful of formerly-prescription medications have moved to OTC after FDA review. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in the United States follows the standard rules of FDA (Food and Drug Administration).
Pharmacy dispensing
US pharmacies — both chain (CVS, Walgreens, Walmart) and independent — dispense Rx medications under state pharmacy board oversight. Pharmacist consultation is encouraged at pickup. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online prescription fulfilment in the US is well-regulated through state-licensed mail-order and tele-prescribing services. Importing prescription medication for personal use is restricted under federal law. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in USD
Retail pricing in the United States depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in the United States? ▾
In the US, most prescription medications require a written or e-prescription from a licensed prescriber. A handful of formerly-prescription medications have moved to OTC after FDA review. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of FDA (Food and Drug Administration).
Is generic Lumigan available in the United States? ▾
Authorised generics of Bimatoprost are typically available in the United States at a lower cost than branded Lumigan, with bioequivalence required by FDA (Food and Drug Administration). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in USD? ▾
Prices in USD vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in the United States.
Lumigan in other countries
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.